CS
ETTX

Credit Suisse’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Credit Suisse’s Portfolio ETTX Stock Details ETTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-69,560
Closed -$757K – 4051
2018
Q3 		$757K Buy
+69,560
New +$731K ﹤0.01% 3059

Other funds holding ETTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Credit Suisse's ETTX Position: Q4 2018 in Review

Credit Suisse sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q4 2018, closing a stake of 69,560 shares — an estimated $757K sold.

Credit Suisse first reported a position in ETTX in Q3 2018 and held it in 1 quarter. The position peaked at $757K in Q3 2018. 20 funds tracked by Wall St. Rank hold ETTX as of Q4 2018.

  • Credit Suisse reported no remaining Entasis Therapeutics Holdings Inc. position as of Q4 2018 after selling out during the quarter.
  • Credit Suisse sold 69,560 Entasis Therapeutics Holdings Inc. shares in Q4 2018, an estimated $757K.
  • Credit Suisse first reported a position in Entasis Therapeutics Holdings Inc. in Q3 2018 and held it in 1 quarter.
  • Credit Suisse's Entasis Therapeutics Holdings Inc. position peaked at $757K in Q3 2018.
  • 20 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q4 2018.

Based on Credit Suisse's 13F filing for Q4 2018, filed 13 Feb 2019.